Skip to main content
LXRX
NASDAQ Life Sciences

Lexicon Q2 2026: $31.8M Loss, SONATA-HCM Enrollment Complete, ZYNQUISTA Resubmission on Track

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.95
Mkt Cap
$1.088B
52W Low
$1.02
52W High
$2.68
52W Position info
91% above low
Off High info
27% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

LXRX sits 91% above its 52-week low of $1.02.

Summary

Lexicon's Q2 2026 loss widened to $31.8M, but the company completed enrollment in its pivotal SONATA-HCM study and expects ZYNQUISTA NDA resubmission in Q4 2026. A new $100M loan facility bolsters cash.


Key Events · Earnings and Guidance · LXRX

  • Q2 2026 Net Loss of $31.8M

    Net loss of $31.8 million, or $0.07 per share, compared to net income of $3.3 million in Q2 2025, driven by absence of prior-year licensing revenue and higher R&D costs.

  • SONATA-HCM Enrollment Complete

    Pivotal Phase 3 SONATA-HCM study in hypertrophic cardiomyopathy fully enrolled, exceeding 500-patient target; top-line data expected Q1 2027.

  • ZYNQUISTA NDA Resubmission Q4 2026

    Resubmission of New Drug Application for ZYNQUISTA in type 1 diabetes anticipated in Q4 2026, supported by ongoing STENO1 safety data.

  • Hercules Capital $100M Loan Facility

    Entered $100 million loan facility in May 2026; $55 million initial tranche funded and used to repay prior Oxford Finance loan.


Analysis · LXRX · Life Sciences

A swing from a $3.3 million profit a year ago to a $31.8 million net loss in Q2 2026 underscores the impact of evaporating licensing revenue and rising R&D costs. Yet the quarter also delivered a critical catalyst: enrollment in the pivotal SONATA-HCM trial finished ahead of schedule, with top-line data now expected in Q1 2027—a milestone that could reshape the outlook for a stock trading near $2. Meanwhile, the ZYNQUISTA NDA resubmission is on track for Q4 2026, and a new $100 million loan facility with Hercules Capital extends the financial runway, though the $190.6 million cash balance and ongoing losses keep capital needs firmly in focus.

At the time of this filing, LXRX was trading at $1.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.02 to $2.68. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LXRX - Latest Insights

LXRX
Aug 06, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $2.11 info
Change: -$0.1844 (-8%) info
Market Cap: $1.088B info
LXRX
Jul 27, 2026, 8:32 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $2.11 info
Change: -$0.1844 (-8%) info
Market Cap: $1.088B info
LXRX
May 08, 2026, 9:42 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $1.96
Real-time Price: $2.11 info
Change: +$0.1456 (+7%) info
Market Cap: $1.088B info
LXRX
May 07, 2026, 4:21 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.68
Real-time Price: $2.11 info
Change: +$0.4256 (+25%) info
Market Cap: $1.088B info
LXRX
May 07, 2026, 7:41 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.66
Real-time Price: $2.11 info
Change: +$0.4456 (+27%) info
Market Cap: $1.088B info